Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%.
Overview
- Phase
- Phase 3
- Intervention
- Pazufloxacin
- Conditions
- Conjunctivitis, Bacterial
- Sponsor
- Laboratorios Sophia S.A de C.V.
- Enrollment
- 46
- Locations
- 6
- Primary Endpoint
- Amount of Conjunctival Secretion Present in Each Patient by the End of Treatment
- Status
- Terminated
- Last Updated
- 4 years ago
Overview
Brief Summary
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis.
Goal:To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the ophthalmic solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis.
Hypothesis:the ophthalmic solution PRO-157 is not inferior in the treatment of bacterial conjunctivitis, compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of the disease.
Number of patients:
160 patients, each one will provide an eye for efficacy analysis, divided into 2 groups (80 eyes per group).
Detailed Description
The study subjects will be recruited from various research centers in western and central Mexico. Each research center has a monitoring plan specified according to the recruitment capabilities of the same, which must be at least once a month, where the queries of your data entered into the electronic case report report will be reported to the center. (e-CRF) for which it has as time limit the next monitoring visit to make the pertinent changes. The report of adverse events will be made according to the standard operating procedure (PNO) where it specifies, according to Official Mexican Standard 220 (NOM 220), that the signs or symptoms of adverse events will be reported based on the Medical Dictionary. for Regulatory Activities, for which the sponsor has version 20.1 in Spanish. For serious adverse events (SAEs) will be reported in accordance with the standardized operation procedure of pharmacovigilance of the sponsor, which adheres to the guidelines of NOM 220 and international regulations, these will be reported in the regulatory framework to the regulatory entity within a period of time no more than 7 days. The study is registered in the National Registry of Clinical Trials (RNEC), entity equivalent to Clinical Trials in Mexico. The quality assurance plan is carried out by the sponsor through the Quality Assurance agent in Clinical Research, whose function is to conduct inspections and audits of the research sites to document and generate reports of deviations from the protocol. In addition to the visits of the monitoring plan, the reliability of the data is guaranteed. To verify the integrity, veracity and reliability of the data entered into the e-CRF, the monitors of each center will check the information uploaded to the portal with that reported in the source document of the principal investigator (PI), such as clinical notes, clinical history and documents. and formats attached to the research protocol, physical case report format, as well as those provided by the sponsor to the PI (subject's diary and quality and satisfaction survey). The e-CRF used for this clinical study is provided by an internationally certified provider with the highest quality standards, protection of information under current regulations and confidentiality guarantee. The information that the PIs enter into the e-CRF is collated and verified by the clinical monitors and by the service provider's personnel, later reviewed and approved by the medical ophthalmologist researcher and by the Clinical Security Pharmacologist, who authorize the monitored data of clinical information and safety of the study molecule, respectively.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent.
- •Age ≥ 1 year.
- •Both genders.
- •Clinical picture of acute bacterial conjunctivitis defined by: Conjunctival secretion and conjunctival bulbar hyperemia
Exclusion Criteria
- •Pregnant women, lactating or planning to become pregnant.
- •Women of reproductive age and who do not have a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction.
- •Participation in another clinical research study ≤ 30 days before the baseline visit.
- •Previous participation in this same study.
- •That they can not comply with their attendance at appointments or with all the requirements of the protocol.
- •Single eye
- •Presence of corneal abrasion or corneal ulceration in the study eye.
- •History Users of contact lenses who are not willing to suspend their use during the study.
- •Users of any formulation with ophthalmic application, including lubricants, that can not, or do not want to suspend it during the study.
- •Antecedents of eye surgery 6 weeks prior to study entry.
Arms & Interventions
PRO-157
Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Intervention: Pazufloxacin
Zymar
Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Intervention: Zymar
Outcomes
Primary Outcomes
Amount of Conjunctival Secretion Present in Each Patient by the End of Treatment
Time Frame: will be evaluated at the end of the treatment (day 8, final visit)
The ocular secretion will be classified as 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The number will be reported according to the rating granted at final visit.
Severeness of Conjunctival Bulbar Hyperemia in Each Patient by the End of Treatment
Time Frame: will be evaluated at the end of the treatment (day 8, final visit)
Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. Will be graduated using the Efron scale. 0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe.
Secondary Outcomes
- Adverse Events(day 0 to day 17 (visit 0 to security call))
- Overall Rating (Global Qualification) of Product's Efficacy as Classified by Main Investigator by the End of Treatment(will be evaluated at the end of the treatment (day 8, final visit))
- Presence of Bacterial Eradication Compared to Baseline Culture Results(will be evaluated at the end of the treatment (day 8, final visit))
- Presence of Clinical Remission Defined as Absence of Hyperemia and Secretion by the Final Visit(will be evaluated at the end of the treatment (day 8, final visit))